BackMedigus Ltd. - Warrants Overview
Medigus Ltd. - Warrants - Series C (23/07/2023)

Medigus Ltd. - Warrants Return on Equity

Latest ROE for Medigus Ltd. - Warrants: -92.44% — see history and peer comparisons.

Get informed when a big investor buys or sells

+ Follow

ROE

-92.44%

Return on Equity

-92.44%

Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.

ROE (Comparison Companies)

Loading

ROE History

Loading

ROE Comparison

Loading

Medigus Ltd. - Warrants (MDGSW) FAQ

Medigus Ltd. - Warrants posts a ROE of -92.44%. That is below the Healthcare sector average of -75.84%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For Healthcare stocks, a ROE near -75.84% is typical. Medigus Ltd. - Warrants's -92.44% is lower that level. That is roughly 21.9% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Medigus Ltd. - Warrants's ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -92.44%; use YoY and peer views to separate noise from signal.

Context for MDGSW's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average -75.84%), and (3) consistency with growth and profitability. This page covers the first two; Medigus Ltd. - Warrants's other metric pages and overview cover the third.

Judging Medigus Ltd. - Warrants against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in ROE easier to interpret. Start with -92.44% here, then scan peer and history charts to see if the gap is persistent.